缺血性腦中風使用血栓溶解劑（rt-PA）治療
Treatment of Ischemic Stroke with Thrombolytic Agents (rt-PA)
缺血性腦中風使用血栓溶解劑（rt-PA）治療可以重新打通阻塞血管，rt-PA (recombinant tissue plasminogen activator) 是一種血栓溶解劑，它的作用就是溶解阻塞血管的血栓，恢復腦部的血流。在中風發作後4.5小時內給予rt-PA治療，效果最佳。 超過這個時間窗口，使用rt-PA的風險可能會大於效益。
Ischemic stroke occurs when a blood clot blocks the blood flow to the brain. Thrombolytic therapy using recombinant tissue plasminogen activator (rt-PA) is a treatment that can dissolve these blood clots, restoring blood flow to the affected area of the brain. The optimal time window for administering rt-PA is within 4.5 hours of the onset of stroke symptoms. Beyond this time frame, the risks of treatment may outweigh the benefits.
其他需要注意的點：
Important considerations:
有動脈瘤或動靜脈畸形者不適用，因為使用血栓溶解劑可能會導致出血，而動脈瘤或動靜脈畸形患者本身就有出血的風險，因此不適合使用。
Patients with aneurysms or arteriovenous malformations: These patients are generally not candidates for thrombolytic therapy because the risk of bleeding is significantly increased.
嚴重肝病需要更詳細的考量。肝臟是合成凝血因子的重要器官，嚴重肝病患者可能存在凝血功能異常，使用血栓溶解劑可能增加出血風險。但具體是否適用，還需要根據患者的個體情況綜合評估。
Patients with severe liver disease may have impaired blood clotting due to the liver's role in producing clotting factors. The decision to administer rt-PA in these patients should be made on a case-by-case basis.
缺血性腦中風的治療是一個時間賽跑。及早使用rt-PA，可以有效地改善患者的預後。但治療前，醫師會仔細評估患者的病情，以確定是否適合使用rt-PA，並密切監測治療過程中的反應。
Time is of the essence in treating ischemic stroke. Early administration of rt-PA can significantly improve outcomes. However, before administering rt-PA, healthcare providers must carefully assess the patient's condition to determine if the benefits outweigh the risks. The patient will be closely monitored during and after treatment.
留言